5-(2-Furanyl)-1,2,3,4,5,6-hexahydro-7H-cyclopenta[b]pyridin-7-one

Metabolite details

Identifier

ORZSZFCROJSVII-UHFFFAOYSA-N

InChI Key

ORZSZFCROJSVII-UHFFFAOYSA-N

IUPAC name

5-(uran-2-yl)-1,2,3,4,5,6-hexahydrocyclopenta[b]pyridin-7-one

Preferred name

5-(2-Furanyl)-1,2,3,4,5,6-hexahydro-7H-cyclopenta[b]pyridin-7-one

INN name

—

Synonym

—

ChEBI

CHEBI:184989

Reactome pathways

• No Reactome pathways listed for this metabolite.

Observed in studies

• Bioaccumulation of therapeutic drugs by human gut bacteria: cross-feeding metabolite analysis (FIA-MS) (E.rectale;S.salivarius assays)
• Diallyl disulfide (DADS) ameliorates intestinal Candida albicans infection by modulating the gut microbiota and metabolites and providing intestinal protection in mice
• Effects of Radiofrequency Field from 5G Communications on fecal microbiome and metabolome profiles in mice
• Intergenerational Association of Gut Microbiota and Metabolism between Perinatal Folic Acid Metabolism and Neural Tube Defects (Feces metabolomics)
• Mechanism of interventional effect and targets of Zhuyu Pill in regulating and suppressing colitis and cholestasis
• Alterations in the gut microbiota and metabolomics of seafarers after a six-month sea voyage

Observed in differential profiles

• G4_Eubacterium_rectale_DMSO_30_vs_G3_Eubacterium_rectale_Duloxetine_47
• G1_PBS_vs_G2_DSS
• Sham_vs_Radiofrequency
• Normal_vs_Neural_Tube_Defect
• Control_vs_ZYP_High_Dose
• Control_0d_vs_Treatment_180d
• Control_0d_vs_Treatment_180d